In this episode, Gideon Korrell breaks down the Federal Circuit’s ruling in Janssen v. Teva, where the court upheld Janssen’s patent on paliperidone palmitate’s unique dosing regimen. He explains why the case matters for pharmaceutical patents, Hatch-Waxman disputes, and the limits of obviousness in drug development.
